The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission.
BACKGROUND
Exclusive enteral nutrition (EEN) achieves variable remission rates in patients with Crohn's disease (CD).


OBJECTIVE
To describe our experience of treating CD with an 8-week course of primary EEN and to study factors affecting treatment outcome.


METHODS
All CD patients treated with EEN in our centre between 2004 and 2007 were included in the study. Remission was determined by a combination of clinical parameters. Disease phenotype was assigned using published classifications. Inflammatory markers and anthropometry (Z-scores) were calculated before and after treatment.


RESULTS
A total of 114 children were treated (four were excluded). Median age at diagnosis was 11.6 years. Fifty-seven (51.8%) were fed orally whilst 53 (48.2%) were fed by tube. Eighty-eight (80%) achieved remission with consequent reductions in erythrocyte sedimentation rate and C-reactive protein (P < 0.001). Patients in remission had comparative improvements in weight (-1.04 cf. -0.40) and BMI Z-scores (-0.98 cf. -0.03) by the end of treatment (P < 0.001). Individuals with isolated terminal ileal disease (n = 4) had lower remission rates than other locations (P = 0.02). No other significant differences in remission rates for any other disease locations were found.


CONCLUSIONS
Exclusive enteral nutrition induces clinical remission, normalization of inflammatory markers and improves weight/BMI Z-scores in most patients. This study demonstrates that disease phenotype should not influence clinicians when commencing patients on EEN.
Buchanan
E
E
Department of Nutrition and Dietetics, Yorkhill Hospital, Glasgow, UK.
Gaunt
W W
WW
Cardigan
T
T
Garrick
V
V
McGrogan
P
P
Russell
R K
RK
D000293:Adolescent; D000886:Anthropometry; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003424:Crohn Disease / Q000628:therapy*; D004750:Enteral Nutrition; D006801:Humans; D010641:Phenotype; D012074:Remission Induction / Q000379:methods
D002097:C-Reactive Protein